The Relationship Between ERCC1 Expression In Circulating Tumor Cells And Prognosis Of Ovarian Cancer

PurposeTo explore the relstionship between ERCC1 gene expression levels in CTC and the prognosis of EOC.MethodFirstly,60 EOC cases were selected among patients diagnosed and treated in our hospital from March 2015 to June 2017.5 ml of peripheral blood were collected within one week after surgery in patients undergoing chemotherapy for CTC and CTC types.Secondly,50 EOC cases was selected among patients in our hospital from March 2015 to June 2017 as research subjects.One week before chemotherapy and one week after completion of three cycles of chemotherapy,5 ml of peripheral blood from EOC patients were sampled to detect ERCC1 gene expression in different types CTC.2.This study used NFM/RNA-ISH to detect ERCC1 gene expression in CTC and CTC classification.Result:1.NFM/RNA-ISH can detect CTC in peripheral blood of EOC patients.CTC is divided into three types:epithelial CTC,mixed CTC,Mesenchymal CTC.Mixed CTC has the highest positive rate.ERCC1 gene expression can be detected in CTC.ERCC1 + CTC is divided into three types:epithelial ERCC1 + CTC,mixed ERCC1 + CTC,Mesenchymal ERCC1 + CTC.The mixed ERCC1 + CTC has the highest positive rate.2.The positive rate of CTC was significantly correlated with the sensitivity of platinum-based drugs in EOC patients(P<0.05).The platinum resistance was significantly higher in patients with CTC-positive EOC.3.The epithelial CTC and Mesenchymal CTC were significantly correlated with platinum sensitivity in CTC-positive EOC patients(P<0.05).In CTC-positive EOC patients,platinum resistance was significantly reduced in patients with epithelial CTC-positive EOC,while platinum resistance was significantly increased in EOC patients with Mesenchymal CTC-positive.4.The postchemotherpy change of ERCC1+CTC in peripheral blood was significantly correlated with the sensitivity of platinum-based drugs in EOC patients(P<0.05).The platinum resistance was significantly higher among EOC patients with higher ERCC1 gene expression in CTC.5.The positive rate of ERCC1 in patients with Mesenchymal CTC-positive EOC was significantly correlated with the sensitivity of platinum-based drugs(P<0.05).Mesenchymal CTC with ERCC1 gene positive expression showed a significant increase in platinum resistance.Conclusion1.NFM/RNA-ISH can effectively detect CTC in peripheral blood of EOC patients.CTC is divided into three types:epithelial CTC,mixed CTC,Mesenchymal CTC.The mixed CTC has the highest positive rate.Also,NFM/RNA-ISH can effectively detect ERCC1 gene expression in CTC.ERCC1 + CTC can be divided into three types:epithelial ERCC1 ＋CTC,mixed ERCC1 + CTC,Mesenchymal ERCC1 + CTC,and the mixed ERCC1 + CTC have the highest positive rate.2.The positive rate of CTC was significantly correlated with the sensitivity of platinum-based drugs in EOC patients(P<0.05).Patients with CTC-positive EOC were more susceptible to platinum resistance.3.The epithelial CTC and mesenchymal CTC were significantly correlated with the sensitivity of platinum-based drugs in CTC-positive EOC patients(P<0.05).Patients with epithelial CTC-positive EOC are more susceptible to platinum-sensitivity in CTC-positive EOC patients;patients with mesenchymal CTC-positive EOC are more susceptible to platinum resistance.4.The number of ERCC1+CTC in peripheral blood after chemotherapy was significantly correlated with the platinum drug resistance of EOC patients(P<0.05).After chemotherapy,the EOC patients with increasing ERCC1 expression of CTC in peripheral blood were more susceptible to platinum resistance.5.The positive rate of ERCC1 in mesenchymal CTC-positive EOC patients was significantly correlated with the sensitivity of platinum-based drugs(P<0.05).The patients with positive expression of ERCC1 gene in mesenchymal CTC were more susceptible to platinum resistance.